Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Finished Goods: 2010-2019

Historic Finished Goods for UNITED THERAPEUTICS (UTHR) over the last 10 years, with Dec 2019 value amounting to $43.2 million.

  • UNITED THERAPEUTICS's Finished Goods fell 7.98% to $43.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $43.8 million, marking a year-over-year decrease of 7.98%. This contributed to the annual value of $43.2 million for FY2019, which is 11.29% down from last year.
  • UNITED THERAPEUTICS's Finished Goods amounted to $43.2 million in FY2019, which was down 11.29% from $48.7 million recorded in FY2018.
  • Over the past 5 years, UNITED THERAPEUTICS's Finished Goods peaked at $55.9 million during FY2017, and registered a low of $35.7 million during FY2015.
  • Over the past 3 years, UNITED THERAPEUTICS's median Finished Goods value was $48.7 million (recorded in 2018), while the average stood at $49.3 million.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 39.22% in 2016, then declined by 12.88% in 2018.
  • Over the past 5 years, UNITED THERAPEUTICS's Finished Goods (Yearly) stood at $35.7 million in 2015, then soared by 39.22% to $49.7 million in 2016, then increased by 12.47% to $55.9 million in 2017, then declined by 12.88% to $48.7 million in 2018, then fell by 11.29% to $43.2 million in 2019.